Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults
NCT ID: NCT02658253
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
68 participants
INTERVENTIONAL
2016-01-31
2019-02-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The safety and the tolerability of the vaccine will be assessed on the rate of solicited and unsolicited events/reactions The safety profile will included local and systemic reactions/events as well as the biological safety, based on a clinically significant change of the baseline value of the main biological criteria
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
NCT02014727
Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted
NCT02647489
Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine
NCT05426187
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
NCT02613520
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
NCT02334462
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Primary objective is to evaluate the safety of 3 different dosages (20µg - 50µg and 100µg) of the PRIMVAC vaccine adjuvanted either with Alhydrogel® or GLA-SE, and administered at D0, D28 and D56 in healthy European and Burkinabe adults.
* Secondary objectives are to assess:
* the humoral immune response to the PRIMVAC vaccine antigen (VAR2CSA) by measuring the variation in the level of total IgG and the level of the isotypic subtypes capable of recognizing the native antigen.
* the cellular immune response by measuring:
* the number of T cell secreting IL5 and IFNg following an ex-vivo stimulation with the vaccine antigen
* the B lymphocyte phenotypes isolated from PBMC
* Exploratory objectives are:
* To explore the quality of the humoral immune response by the measure of the capability of the antibodies specific to the vaccine antigen to:
* Cross-react with different VAR2CSA variants expressed on the surface of erythrocytes infected by various strains of Plasmodium falciparum,
* Inhibit interactions between parasitized erythrocytes expressing different VAR2CSA variants and Chondroitin Sulfate A (receptor involved in placental sequestration),
* Promote opsonic phagocytosis of parasitized erythrocytes with various strains of Plasmodium falciparum expressing different VAR2CSA variants
* To explore the quality of the cellular immune response induced by the vaccine antigen by the quantitation of a large panel of cytokines in the ELISpot supernatants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A1:Primvac 20 µg +alhydrogel
Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Alhydrogel
0.85 mg og Aluminium content
Group A2:Primvac 20 µg +GLA-SE
Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
GLA-SE
2.56 µg of GLA content
Group B1:Primvac 50 µg +alhydrogel
Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Alhydrogel
0.85 mg og Aluminium content
Group B2:Primvac 50 µg +GLA-SE
Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
GLA-SE
2.56 µg of GLA content
Group C1:Primvac 50 µg +alhydrogel
Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Alhydrogel
0.85 mg og Aluminium content
Group C2: Primvac 50 µg +GLA-SE
Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
GLA-SE
2.56 µg of GLA content
Group C3: Placebo
Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)
Vaccination schedule: D0, D28 and D56
Placebo
0.9% Na cl
Group D1:Primvac 100 µg +alhydrogel
Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Alhydrogel
0.85 mg og Aluminium content
Group D2: Primvac 100 µg +GLA-SE
Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE
Vaccination schedule: D0, D28 and D56
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
GLA-SE
2.56 µg of GLA content
Group D3: placebo
Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)
Vaccination schedule: D0, D28 and D56
Placebo
0.9% Na cl
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRIMVAC
3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
GLA-SE
2.56 µg of GLA content
Alhydrogel
0.85 mg og Aluminium content
Placebo
0.9% Na cl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female of age ≥18 years to ≤35 years
* Healthy as a result of review of medical history and/or clinical examination at the time of screening and clinical judgment of the investigator
* Available for the duration of the trial (15 months)
* Willingness to use reliable contraceptive methods such as: birth control pills or birth control patches or vaginal ring, diaphragm, IUD (intrauterine device), condom, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment at V0 and up to 4 weeks after last vaccination (V6)
* Volunteer reachable by phone during the entire study duration
* Individuals affiliated to a social security regimen
* Volunteer registered in the French Health ministry computerized file and authorized to participate in a clinical trial
* Written informed consent (must be obtained prior initiation of any study related intervention)
* Nulligest Female of age ≥18 years to ≤35 years
* Healthy as a result of review of medical history and/or clinical examination at the time of screening and clinical judgment of the investigator
* Available for the duration of the trial (15 months)
* Willingness to use reliable contraceptive methods such as: birth control pills or birth control patches or vaginal ring, diaphragm, IUD (intrauterine device), condom, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment at V0 and up to 4 weeks after last vaccination (V6)
Exclusion Criteria
* Intention to become pregnant during the trial
* Volunteers who are not able to understand and to follow all required study procedures for the whole period of the study in the opinion of the investigator.
* Volunteers with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
* Volunteers participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
* History of psychiatric condition that may affect participation in the study (i.e. depression, anti-depressant treatment).
* Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the study data based on investigator's judgment.
* Any history of malaria infection.
* Travel to a malaria endemic region during the study period or within the six months preceding enrolment in the study.
* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
* History of a serious adverse reaction to any vaccine, including Guillain-Barre Syndrome.
* Administration or planned administration of a vaccine or gammaglobulin not foreseen by the clinical trial protocol within 30 days prior to the first immunization and up to 4 weeks after the last immunization.
* Volunteers with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
* Administration of immunoglobulins and/or any blood products within the three months preceding the inclusion.
* Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 3 months (inhaled and topical steroids are allowed)
* Seropositive for hepatitis B virus surface antigen (HBsAg)
* Seropositive for hepatitis C virus (antibodies to HCV)
* Seropositive for human immunodeficiency virus (antibodies to HIV 1-2)
* Any other serious chronic illness requiring hospital specialist supervision.
* Any clinically significant abnormal finding on screening biochemistry or hematology blood tests or urinalysis
* Symptoms, physical signs or laboratory values suggestive of systemic disorders, including infectious renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.
* Volunteer under guardianship or legal incapacitation.
* Pregnancy ongoing as determined by a positive urinary test
* Intention to become pregnant during the trial
* Volunteers who are not able to understand and to follow all required study procedures for the whole period of the study in the opinion of the investigator.
* Volunteers with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
* Volunteers participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
* History of psychiatric condition that may affect participation in the study (i.e. depression, anti-depressant treatment).
* Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data, based on investigator's judgment.
* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
* History of a serious adverse reaction to any vaccine, including Guillain-Barre syndrome.
* Administration or planned administration of a vaccine or gammaglobulin not foreseen by the clinical trial protocol within 30 days prior to the first immunization and up to 4 weeks after the last immunization.
* Volunteers with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
* Administration of immunoglobulins and/or any blood products within the three months preceding the inclusion.
* Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 3 months (inhaled and topical steroids are allowed).
* Seropositive for hepatitis B virus surface antigen (HBsAg).
* Seropositive for hepatitis C virus (antibodies to HCV).
* Seropositive for human immunodeficiency virus (antibodies to HIV 1-2).
* Any other serious chronic illness requiring hospital specialist supervision.
* Any clinically significant abnormal finding on screening biochemistry or hematology blood tests or urinalysis
* Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.
* Volunteer under guardianship or legal incapacitation.
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Vaccine Initiative
OTHER
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
OTHER
Centre national de recherche et de formation sur le paludisme
OTHER_GOV
EUCLID Clinical Trial Platform
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Odile Launay, Professor
Role: STUDY_CHAIR
Institut National de la Santé Et de la Recherche Médicale, France
Benoit GAMAIN, Dr
Role: STUDY_DIRECTOR
Institut National de la Santé Et de la Recherche Médicale, France
Sodiomon SIRIMA, Dr
Role: STUDY_CHAIR
Centre national de recherche et de formation sur le paludisme
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CNRFP
Ouagadougou, , Burkina Faso
CIC 1417
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chene A, Gangnard S, Guadall A, Ginisty H, Leroy O, Havelange N, Viebig NK, Gamain B. Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC. EBioMedicine. 2019 Apr;42:145-156. doi: 10.1016/j.ebiom.2019.03.010. Epub 2019 Mar 15.
Gamain B, Chene A, Viebig NK, Tuikue Ndam N, Nielsen MA. Progress and Insights Toward an Effective Placental Malaria Vaccine. Front Immunol. 2021 Feb 25;12:634508. doi: 10.3389/fimmu.2021.634508. eCollection 2021.
Sirima SB, Richert L, Chene A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouedraogo A, Nebie I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konate E, Roussillon C, Kante M, Belarbi L, Diarra A, Henry N, Soulama I, Ouedraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2020 May;20(5):585-597. doi: 10.1016/S1473-3099(19)30739-X. Epub 2020 Feb 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-002246-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
C14-60
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.